Juneflecad (Flecainide Acetate)

• Juneflecad is indicated for cardiac rhythm disorders where rapid electrical conduction contributes to arrhythmia.
• Ventricular arrhythmias: restores normal ventricular rhythm and reduces life‑threatening tachycardia episodes.
• Supraventricular arrhythmias (e.g., atrial fibrillation): decreases the frequency of irregular atrial beats and helps maintain sinus rhythm.
• Paroxysmal supraventricular tachycardia: terminates episodes by slowing atrioventricular conduction.

• Flecainide acetate blocks fast inward sodium channels in cardiac myocytes, which prolongs the refractory period and slows impulse propagation through the myocardium. By reducing the rate of depolarization, it diminishes abnormal automaticity and re‑entry circuits, thereby stabilising cardiac electrical activity and preventing arrhythmic events.

Common Side Effects

• Dizziness: sensation of light‑headedness or unsteadiness.
• Visual disturbances: blurred vision or altered color perception.
• Headache: mild to moderate pain in the head region.
• Nausea: feeling of queasiness often accompanied by an urge to vomit.

Serious or Rare Side Effects

• Proarrhythmia: new or worsening arrhythmias, including ventricular tachycardia.
• Severe bradycardia: markedly slowed heart rate that may cause hypotension.
• Atrioventricular block: impaired conduction between atria and ventricles.
• Sudden cardiac death: unexpected fatal cardiac event, particularly in patients with structural heart disease.

Before initiating therapy, clinicians should evaluate cardiac status and monitor for adverse reactions.

• ECG monitoring: perform baseline and periodic electrocardiograms to detect conduction changes.
• Renal/hepatic function: assess organ function as impairment may alter drug clearance.
• Structural heart disease: avoid use in patients with prior myocardial infarction or significant cardiomyopathy.
• Concomitant CYP2D6 inhibitors: adjust therapy if strong inhibitors are co‑administered.
• Store at room temperature: keep in the original packaging, protect from moisture and direct sunlight.

Flecainide may interact with several cardiovascular and metabolic agents.

Major Interactions (Avoid)

• Other Class I antiarrhythmics (e.g., quinidine, propafenone): additive sodium‑channel blockade can precipitate severe conduction delay.
• Strong CYP2D6 inhibitors (e.g., paroxetine, fluoxetine): increase flecainide plasma concentrations and risk of toxicity.
• Drugs that markedly prolong QRS duration (e.g., amiodarone): synergistic effect on ventricular conduction.

Moderate Interactions (Monitor Closely)

• Beta‑blockers (e.g., metoprolol): may enhance bradycardic effects; monitor heart rate.
• Calcium‑channel blockers (e.g., verapamil): can increase plasma levels; adjust dosage if needed.
• Diuretics causing electrolyte shifts (e.g., furosemide): monitor potassium and magnesium to prevent proarrhythmic risk.